Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease

A single-blind, intrapatient left-to-right controlled study

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background Nail psoriasis is difficult to treat. The efficacy of pulsed dye laser (PDL) therapy for nail psoriasis has been reported in non-placebo controlled studies. Objective To evaluate the efficacy and safety of PDL with topical retinoid in the treatment of nail psoriasis. Methods The study was an intrapatient, left-to-right controlled trial of PDL in 25 patients with recalcitrant, bilateral fingernail psoriasis recruited between February 2011 and August 2011. We included two groups of patients: (1) patients with severe psoriasis who were receiving stable systemic therapy (phototherapy and systemic medication); (2) patients with mild psoriasis who were not receiving systemic therapy. One hand received the experimental treatment (PDL and tazarotene 0.1% cream) and the other, the control treatment (tazarotene 0.1% cream). All five fingernails of the experimental hand were treated with 595-nm PDL once a month for 6 months. Assessments included the modified Nail Psoriasis Severity Index (NAPSI) at baseline, 3, and 6 months, the Physician's Global Assessment at 3 and 6 months, the patient's global assessment, and adverse events. Results Nineteen patients completed the 6-month protocol. The mean decrease in modified NAPSI score from baseline to 6 months was significantly more after the experimental treatment than the control treatment. Physician's global assessment showed significantly higher percentage of patients had ≥75% improvement at 6 months in the experimental group than the control group (31.6% vs. 5.3%, P = 0.045). Scores on the patient's global assessment were significantly higher in the experimental group than the control group (P <0.001). Conclusion PDL plus topical tazarotene 0.1% cream is an effective and safe therapy in the treatment of nail psoriasis.

Original languageEnglish
Pages (from-to)102-107
Number of pages6
JournalLasers in Surgery and Medicine
Volume45
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Nail Diseases
Dye Lasers
Psoriasis
Nails
Therapeutics
Hand
Physicians
tazarotene
Control Groups
Phototherapy
Retinoids
Laser Therapy

Keywords

  • psoriasis
  • psoriatic nail
  • pulsed dye laser
  • tazarotene

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

@article{11ab8dcfb2594de19c6f99462b048c1b,
title = "Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: A single-blind, intrapatient left-to-right controlled study",
abstract = "Background Nail psoriasis is difficult to treat. The efficacy of pulsed dye laser (PDL) therapy for nail psoriasis has been reported in non-placebo controlled studies. Objective To evaluate the efficacy and safety of PDL with topical retinoid in the treatment of nail psoriasis. Methods The study was an intrapatient, left-to-right controlled trial of PDL in 25 patients with recalcitrant, bilateral fingernail psoriasis recruited between February 2011 and August 2011. We included two groups of patients: (1) patients with severe psoriasis who were receiving stable systemic therapy (phototherapy and systemic medication); (2) patients with mild psoriasis who were not receiving systemic therapy. One hand received the experimental treatment (PDL and tazarotene 0.1{\%} cream) and the other, the control treatment (tazarotene 0.1{\%} cream). All five fingernails of the experimental hand were treated with 595-nm PDL once a month for 6 months. Assessments included the modified Nail Psoriasis Severity Index (NAPSI) at baseline, 3, and 6 months, the Physician's Global Assessment at 3 and 6 months, the patient's global assessment, and adverse events. Results Nineteen patients completed the 6-month protocol. The mean decrease in modified NAPSI score from baseline to 6 months was significantly more after the experimental treatment than the control treatment. Physician's global assessment showed significantly higher percentage of patients had ≥75{\%} improvement at 6 months in the experimental group than the control group (31.6{\%} vs. 5.3{\%}, P = 0.045). Scores on the patient's global assessment were significantly higher in the experimental group than the control group (P <0.001). Conclusion PDL plus topical tazarotene 0.1{\%} cream is an effective and safe therapy in the treatment of nail psoriasis.",
keywords = "psoriasis, psoriatic nail, pulsed dye laser, tazarotene",
author = "Yu-Chen Huang and Chou, {Chia Lun} and Chiang, {Ying Yi}",
year = "2013",
month = "2",
doi = "10.1002/lsm.22122",
language = "English",
volume = "45",
pages = "102--107",
journal = "Lasers in Surgery and Medicine",
issn = "0196-8092",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease

T2 - A single-blind, intrapatient left-to-right controlled study

AU - Huang, Yu-Chen

AU - Chou, Chia Lun

AU - Chiang, Ying Yi

PY - 2013/2

Y1 - 2013/2

N2 - Background Nail psoriasis is difficult to treat. The efficacy of pulsed dye laser (PDL) therapy for nail psoriasis has been reported in non-placebo controlled studies. Objective To evaluate the efficacy and safety of PDL with topical retinoid in the treatment of nail psoriasis. Methods The study was an intrapatient, left-to-right controlled trial of PDL in 25 patients with recalcitrant, bilateral fingernail psoriasis recruited between February 2011 and August 2011. We included two groups of patients: (1) patients with severe psoriasis who were receiving stable systemic therapy (phototherapy and systemic medication); (2) patients with mild psoriasis who were not receiving systemic therapy. One hand received the experimental treatment (PDL and tazarotene 0.1% cream) and the other, the control treatment (tazarotene 0.1% cream). All five fingernails of the experimental hand were treated with 595-nm PDL once a month for 6 months. Assessments included the modified Nail Psoriasis Severity Index (NAPSI) at baseline, 3, and 6 months, the Physician's Global Assessment at 3 and 6 months, the patient's global assessment, and adverse events. Results Nineteen patients completed the 6-month protocol. The mean decrease in modified NAPSI score from baseline to 6 months was significantly more after the experimental treatment than the control treatment. Physician's global assessment showed significantly higher percentage of patients had ≥75% improvement at 6 months in the experimental group than the control group (31.6% vs. 5.3%, P = 0.045). Scores on the patient's global assessment were significantly higher in the experimental group than the control group (P <0.001). Conclusion PDL plus topical tazarotene 0.1% cream is an effective and safe therapy in the treatment of nail psoriasis.

AB - Background Nail psoriasis is difficult to treat. The efficacy of pulsed dye laser (PDL) therapy for nail psoriasis has been reported in non-placebo controlled studies. Objective To evaluate the efficacy and safety of PDL with topical retinoid in the treatment of nail psoriasis. Methods The study was an intrapatient, left-to-right controlled trial of PDL in 25 patients with recalcitrant, bilateral fingernail psoriasis recruited between February 2011 and August 2011. We included two groups of patients: (1) patients with severe psoriasis who were receiving stable systemic therapy (phototherapy and systemic medication); (2) patients with mild psoriasis who were not receiving systemic therapy. One hand received the experimental treatment (PDL and tazarotene 0.1% cream) and the other, the control treatment (tazarotene 0.1% cream). All five fingernails of the experimental hand were treated with 595-nm PDL once a month for 6 months. Assessments included the modified Nail Psoriasis Severity Index (NAPSI) at baseline, 3, and 6 months, the Physician's Global Assessment at 3 and 6 months, the patient's global assessment, and adverse events. Results Nineteen patients completed the 6-month protocol. The mean decrease in modified NAPSI score from baseline to 6 months was significantly more after the experimental treatment than the control treatment. Physician's global assessment showed significantly higher percentage of patients had ≥75% improvement at 6 months in the experimental group than the control group (31.6% vs. 5.3%, P = 0.045). Scores on the patient's global assessment were significantly higher in the experimental group than the control group (P <0.001). Conclusion PDL plus topical tazarotene 0.1% cream is an effective and safe therapy in the treatment of nail psoriasis.

KW - psoriasis

KW - psoriatic nail

KW - pulsed dye laser

KW - tazarotene

UR - http://www.scopus.com/inward/record.url?scp=84874452930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874452930&partnerID=8YFLogxK

U2 - 10.1002/lsm.22122

DO - 10.1002/lsm.22122

M3 - Article

VL - 45

SP - 102

EP - 107

JO - Lasers in Surgery and Medicine

JF - Lasers in Surgery and Medicine

SN - 0196-8092

IS - 2

ER -